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NEUTROPHILS generate potent microbicidal molecules via
the oxygen-dependent pathway, leading to the genera-
tion of reactive oxygen intermediates (ROD, and via the
non-oxygen dependent pathway, consisting in the re-
lease of serine proteinases and metalloproteinases stored
in granules. Over the past years, the concept has emerged
thatboth ROI and proteinases canbeviewed as mediators
able to modulate neutrophil responses as well as the
whole inflammatory process. This is well illustrated by
the oxidative regulation of proteinase activity showing
that oxidants and proteinases acts is concert to optimize
the microbicidal activity and to damage host tissues. ROI
and proteinases can modify the activity of several pro-
teins involved in the control of inflammatory process.
Among them, tumour necrosis factor-z and interleukin-8,
are elective targets for such a modulation. Moreover, ROI
and proteinases are also able to modulate the adhesion
process of neutrophils to endothelial cells, which is a
critical step in the inflammatory process.
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Introduction
The aim of this report is to review our current
understanding of radical oxygen intermediates (ROI)
and proteinases in the context of a modulatory role
of neutrophils in the inflammatory process. We will
also review studies showing that besides their usual
microbicidal role these molecules have important
regulatory functions. The notion that inflammation is
the net result of pro- and contra-inflammatory path-
ways is well illustrated by ROI and proteinases
which either alone, or in concert, may interact in up
or down regulating the major inflammatory process.
Added to the intrinsic complexity of the subject is the
diversity of effects that can be mediated by ROI and
proteinases, either on the phagocyte itself or on the
target cells.
Neutrophil-derived oxidants and
proteinases
Neutrophils react to invading microorganisms and
inflammatory mediators with a variety of coordinated
responses, such as motility in response to
chemotactic agents, cytoskeletal rearrangement,
phagocytosis, and production of toxic mediators to
allow the neutrophil to destroy pathogens. Although
critical to host defence, neutrophils can damage
normal cells and dissolve connective tissues by the
release of a complex assortment of deleterious
agents, including ROI and proteinases, leading to
inflammatory disorders. 2,3
Conventionally, two microbicidal pathways are de-
fined, depending on whether or not they require
oxygen. The oxygen dependent pathway depends
on ROI whose production follows the activation of
NADPH oxidase; the non-oxygen-dependent path-
way reflects the actions of preformed enzymes and
antimicrobial proteins stored in the neutrophil cyto-
plasmic granules and released upon activation as
illustrated in Fig. 1.
Oxidative metabolism activation, known as the
respiratory burst, first involves NADPH oxidase,
which is an enzymatic complex composed of
cytosolic and membrane proteins which ultimately
translocate to the plasma membrane, leading to the
generation of superoxide anion (O). The
dismutation ofO can generate hydrogen peroxide
(H,.O,). Myeloperoxidase (MPO), an enzyme con-
tained in azurophilic granules, in the presence of
chloride and H202, catalyses the formation of potent
chlorinated oxidants such as hypochlorous acid
(HOCl) and chloramines, the so-called long-lived
oxidants.4-* Much of what is known about the
NADPH oxidase has come from studies of patients
deficient in the system, who have chronic
granulomatous disease (CGD). Owing to a genetic
defect in the major component of the oxidase,
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FIG 1. Neutrophil effector mechanisms involved in the defence against pathogens and in the modulation of inflammatory process. Neutrophils
respond to inflammatory agents by expressing membrane receptors appropriate to the stimulation and by developing coordinated responses such
as spreading, diapedesis, phagocytosis, production and release of toxic effector molecules. The selectins and the leukocyte integrins of the CD18
family, including LFA-1 (CD11a/CD18), CR3 (CD11b/CD18), p150 (CD11c/CD18), are necessary for proper adhesion to endothelium. The
complement opsonins C3b and C4b are recognized by CRI. IgG opsonins are recognized via the immunoglobulin receptors (FcyR). The stimulus
dependent expression of these receptors is required for phagocytosis, degranulation and respiratory burst. The first microbicidal pathway is the
oxidative reponse which consists of the production of ROI following NADPH-oxidase complex activation, including superoxide anion (O), hydrogen
peroxide (H202) and via myeloperoxidase, hypochlorous acid (HOCI) and chloramines. The second microbicidal pathway is non-oxygen dependent
and consists in the release in the phagolysosome or in the extracellular medium, of preformed proteins stored in granules. The serprocidins (serine
proteases with antibiotic activity including elastase, cathepsin G, proteinase 3 and azurocidin) as well as myeloperoxidase are contained in the
azurophilic granules. The metalloproteases (collagenase and gelatinase) are contained in specific and tertiary granules (for gelatinase only).
namely cytochrome b-245, or in cytosolic factors,
phagocytes of CGD patients fail to mount a
respiratory burst. Although their phagocytic capacity
is normal, CGD phagocytes are incapable of
producing ROI and of subsequently killing ingested
pathogens.9,1
Neutrophils contain several thousand cytoplasmic
granules which act as storage compartments for
macromolecules destined for secretion, stored in
specific granules, or for fusion with phagosomes,
stored in azurophilic granules. 11-13 Neutrophils must
degrade the connective tissues to extravasate and
migrate to the site of inflammation. For this, they
contain metalloproteinases such as collagenase,
stored in the specific granules and gelatinase, stored
in tertiary granules. The azurophilic granules contain
the majority of the antibiotic proteins. Among the ten
identified so far, two are thought to be unique in
primary structuremlysosyme and bactericidal/perme-
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ability increasing protein (BPI). 14a5 The remaining
eight fall into two families, each with four members:
the defensins6 on the one hand, and the serprocidins
(serine proteinases with microbicidal activity) includ-
ing elastase, cathepsin G, proteinase 3 and their
enzymatically inactive homologue azurocidin, on the
other.7
In neutrophils, ROI have indeed traditionally
been viewed primarily as potent microbicidal agents.
We would like to focus on the two paradigms that
(1) despite the clearcut distinction between oxygen-
dependent or non-dependent toxic mechanisms,
the neutrophil is constructed to use both the
NADPH oxidase system and the granule constituents
in a cooperative and concerted manner and to
realize its ultimate destructive potential; and (2)
besides their toxic effects, ROI and proteases at
lower concentrations may cooperate with other
immunomodulatory molecules such as cytokines andModulatory role of neutrophil-derived oxidants and proteinases
adhesion molecules, and thus function as intercellu-
lar signalling molecules and to regulate phagocyte
functions and modulate the overall inflammatory
process.
Neutrophil-derived reactive oxygen intermediates:
Biochemical basis ofROI-mediated effects. An ex-
tensive report on mechanisms of cell injury by ROI
will not be given; the reader can easily find several
reviews on this subject in the literature. 18,19 Neverthe-
less, a brief outline of ROI biochemistry will be
presented. There are three intermediates in the re-
duction of O, to HiO,. As a result, O, H20 and the
hydroxyl radical (OH) are formed by successive one
electron additions. Despite numerous studies, the
formation of OH in phagocytes is still controver-
sial.2-3 So is the formation of singlet oxygen. 24,25
However, in this review, the term ROI will include
O, H,.O,., OH, singlet oxygen and chlorinated
oxidants such as HOC1 and chloramines, and the
defined oxygen species will be specified when
possible.
Although the hallmark of the phagocyte remains
the major source of ROI following NADPH oxidase
activation, other cells can generate ROI through dif-
ferent pathways. Perhaps the most significant source
of non-leukocyte generated ROI is the production of
superoxide anion by xanthine oxidase, observed in
ischaemia/reperfusion injury. 26,27 The cellular altera-
tions following hypoxia promote the conversion of
xanthine dehydrogenase to xanthine oxidase. Many
other potential mechanisms derived from normal
cellular metabolism could result in ROI generation,
including mitochondrial transport, peroxisomal reac-
tions and arachidonate metabolism. ’8
Free radicals and related oxidants have long been
studied as agents of tissue damage. Lipid
peroxidation is a well documented free radical chain
reaction which can be initiated by OH or transition
metal complexes and remains an archetype of ROI-
mediated toxicity. 29-31 Yet few studies have focused
on its involvement in neutrophil oxidative reactions.
Likewise, numerous studies have characterized the
mechanisms underlying oxidative damage to RNA
and DNA.3-4
In contrast, the reactions of proteins with various
radicals/oxidants have not been so extensively stud-
ied although it is now clear that amino acids,
peptides and proteins are, indeed, vulnerable to
attack by a variety of ROI. Oxidation of particularly
sensitive amino acid residues, aggregation or cross-
linking, fragmentation and loss of enzymatic or other
functional properties are but a few of the docu-
mented examples.5-41
Sulfhydryl groups can play an essential role in the
function of several proteins, such as catalytic activity
of enzymes and receptor binding capacity. These
sulfhydryl groups are especially vulnerable to
oxidative attack, with conversion to S-S bonds, par-
ticularly in the presence of metal ions. ROI, and
particularly HOCl and chloramines, are all able to
oxidize sulfhydryl groups resulting in the formation
of a disulfide bridge. This oxidation could be cor-
rected by thiol-containing molecules such as
glutathione (GSH).42,43
Ultimately, oxidatively damaged proteins which
exhibit higher proteolytic susceptibilities than other
damaged proteins serve no useful role, and will
be removed by specific proteolytic degradation. It
is now clear that proteasome, a 670 kDa ATP-
independent proteinase complex (also called
macroxyproteinase) is responsible for most of the
selective degradation of oxidatively modified pro-
teins. This enzymatic complex exhibits a serine
proteinase activity, a sulfhydryl proteinase activity
and a metallo-peptidase activity.44-46 The primary,
secondary or tertiary structure of proteins may be
altered depending on the oxidant and the overall
result may be denaturation and increased
hydrophobicity.47
Besides drastic oxidative attack on a protein, ROI
may affect protein function by the oxidation of a
critical residue in its active site with minor modifica-
tion in the secondary or tertiary structure of the
protein. This type of reaction could be defined more
as ’oxidative regulation
’48 than ’oxidative attack’.
Many proteins may be oxidatively inactivated be-
cause of the sensitivity of methionine residues to
oxidation. Much evidence suggests that methionine
oxidation and subsequent loss of protein activity not
only occur widely in living systems but are
physiologic, homeostatic processes.49 In some cases,
methionine oxidation may occur without changes in
physical or immunochemical properties and without
loss of biologic activity, as is the case for the bovine
growth hormone and the human x2-plasmin inhibi-
tor.5,5 Among the oxidants produced by activated
neutrophils following the respiratory burst, H,.O,. and
the MPO-derived oxidants, namely HOCl and
chloramines appear to be of biological relevance. By
virtue of its strong oxidant potential, HOC1 seems to
be the toxic species used by neutrophils to mediate
cell injury. Chloramines (N-chloroamine) arise from
the chlorination of a wide spectrum of amine-con-
taining compounds by HOC1.6,52 Although these spe-
cies differ in their reactivity with susceptible target
molecules, they are able to mediate diverse biologic
effects, ranging from the modulation of cellular func-
tions to the induction of cell lysis. Chloramines have
a half-life greater than radical oxygen species, rang-
ing from 5 h at 37C to more than 100 h at 4C,
depending on the surrounding environmental con-
centration of anti-oxidant. As a result, they can per-
sist at sites of inflammation long after the disappear-
ance of other oxygen metabolites, and have been
termed long-lived oxidants. Generated chloramines
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are a mixture of chlorinated endogenous and
exogenous amines of molecular weight ranging from
150 to 50 000. 53 The presence of exogenous amine-
containing compounds can influence both the quan-
tity and the characteristics of the long-lived oxidants
generated. For example, the plasma protein albumin
can be chlorinated and retain long-lived oxidant
activity. The presence of appropriate nitrogenous
compounds in the extracellular medium can result in
the generation of lipophilic N-Cl oxidants of a strong
cytotoxic potential. However, only hydrophilic
chloramines are detected in supernatants from stimu-
lated cells. Of primary physiologic importance
among the hydrophilic generated chloramines is N-
chlorotaurine formed by chlorination of the sulfur-
containing amino acid taurine, which is plentiful in
neutrophils. 54 Taurine is the major amine released
into the supernatants of triggered neutrophils, 52 and
thus its chloramine derivative is the most abundant. 53
Taurine chloramine is not a potent toxin but does
oxidize proteins by specific attack at thioether moi-
eties. The notion that methionine oxidation may be
a relevant mechanism by which many proteins are
regulated is corroborated by the fact that this oxida-
tion can be reversed by methionine sulfoxide
reductase, an enzyme which reduces methionine
sulfoxide to methionine, using thioredoxin as
cofactor. 55 The ability of this enzyme to reduce
methionine sulfoxide in a variety of proteins suggests
that it has broad specificity. It has been cloned and
expressed in Escherichia coli. 56 Interestingly enough,
it is widely distributed in different organs and in
particular has been found at high concentration-in
neutrophil extracts. The ability of methionine
sulfoxide reductase to reduce methionine sulfoxide
residues suggests that it may be a repair enzyme for
proteins inactivated by oxidation, or may participate
in a novel type of post-translational regulation of
proteins involved in the inflammatory process.
Antioxidant-mediated cellprotection. Several anti-
oxidant systems or ROI scavengers can protect tissue
from oxidative damage. 5: Antioxidant defences ap-
pear to be an elaborate arsenal of antioxidants which
function in concert to scavenge and detoxify ROI
(superoxide dismutase (SOD), catalase, glutathione
peroxidase), block free radical chain reactions
(tocopherol, carotenoids and ascorbic acid), or se-
quester transition metals which can serve as a ready
source of free electrons (lactoferrin, ceruloplasmin
and transferrin). 58
Owing to the chemical nature of ROI, especially.
radical species, it was difficult to measure these
species directly. Thus, besides their physiologic
role, ROI scavengers provide useful pharmacologic
tools to probe cellular reactions in order to demon-
strate the involvement of ROI in the underlying
mechanisms.
Oxidants have regulatory effects by modulating
antioxidant defences. Glutathione (GSH), the major
non-protein thiol, is present in virtually all cell types
and is involved in numerous biological functions. 59 It
can act as a co-enzyme, an antioxidant by preserving
intracellular reducing conditions, a regulatory mol-
ecule in cell cycle initiation and progression
6 and in
microtubule formation.61
Regulation of intracellular content of GSH in
lymphocytes has been shown to modify immune
response capacity. The sensitivity of lymphocytes to
oxidants is well established. For example, H20 im-
pairs the proliferative capacity of human blood
lymphocytes.’,3 Several lymphocyte functions, such
as mitogen-induced proliferation, natural killer
activity, generation of immunoglobulins, are sensi-
tive to the myeloperoxidase-HiOi--chloride sys-
tem.4,5 Thiol compounds, including GSH, are of
critical significance.6 The proliferative response is
directly related to GSH availability.: Neutrophil
derived chloramines markedly inhibit lympho-
cyte mitogen-induced proliferative response by
decreasing GSH content.8 GSH is involved in
cytokine metabolism. It regulates interleukin-2 and
interleukin-4 activity on cytotoxic T cells.9,: Interest-
ingly, in an in vitro model of chronic HIV infection,
GSH inhibits the induction of HIV expression sug-
gesting that antioxidant therapy may be effective in
limiting progression of the disease process.
:1
The importance of oxidant-mediated injury has
prompted research on new antioxidant therapy by
gene therapy. In vitro evaluation of the regulation of
catalase gene expression in human airway epithelial
cells has shown that the expression of the human
catalase gene is not upregulated in these cells in
response to hyperoxia, because the 5’-flanking re-
gion of the gene has characteristics of a non-regu-
lated ’housekeeping’ gene and does not respond to
a hyperoxic stimulus. However, when human airway
epithelial cells are infected with an adenoviral vector
containing human catalase cDNA, catalase activity
increases, as does the survival of cells subjected to
oxidant stress.:" A similar antioxidant strategy is effi-
cient in protecting endothelial cells against H202-
mediated injury.:3
Neutrophil-derived metalloproteinases and serine
proteinases: Neutrophil-derived proteinases are
packed in granules which are released upon cell
activation. Granule biogenesis follows the
granulocyte differentiation pathway. The azurophilic
granules first emerge at the stage of promyelocytes
and contain neutral serine proteinases. Later in differ-
entiation, at the stage of metamyelocytes, specific
granules containing collagenase and gelatinase
emerge74,:5 However, a tertiary granule population
containing gelatinase has been identified. The
mechanisms underlying the secretion of the three
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morphologically distinct populations of granules
may be under separate control. The order of
exocytosis observed after ionophore-induced eleva-
tion of cytosolic calcium was gelatinase granules,
specific granules, and lastly azurophilic granules.76
Metalloproteinases. Matrix metalloproteinases
(MMPs) consitute a family of closely related enzymes
which play important roles in a variety of physiologi-
cal and pathological processes of matrix degradation.
Human neutrophils contain both a collagenase and
a gelatinase. One of the most intriguing aspects of
the physicochemical properties of these neutrophil
metalloproteinase is the fact that the enzyme can be
isolated from the cell in a latent, inactive form.
Neutrophil collagenase has been isolated as a 91 kDa
latent enzyme that could be activated to yield active
collagenase of 64 kDa which can degrade native
interstitial collagens. Neutrophil gelatinase has also
been isolated in its latent form, with reported mo-
lecular weights of 92, 130 and 225 kDa. The molecu-
lar basis underlying the latency of gelatinase has not
been studied as extensively as that for collagenase.
Collagenase attacks native interstitial collagen
whereas gelatinase only degrades denatured colla-
gen as well as native type IV or type V collagen7:
Human neutrophil collagenase and gelatinase have
been cloned.8,9 Comparison of the primary struc-
tures of MMPs shows that they are structurally ho-
mologous with defined functional domains.8,1 All
these enzymes contain an essential catalytic zinc-
binding domain, an NHi-terminal domain which pre-
serves the latent state of the enzyme and a COOH-
terminal domain which plays a major role in substrate
specificity. In the case of neutrophil collagenase,
mutagenesis analysis has shown that substrate
specificity is determined by a 16 amino-acid se-
quence in the COOH-terminal domain and is influ-
enced by the integrity of a disulfide defined loop at
the COOH-terminal for maximal activity. In addition,
mutation of a critical aspartic residue at position 253
within the presumptive zinc-binding locus resulted
in complete loss of proteolytic activity, suggesting
that this aspartic residue might function as one of the
ligands for divalent cations, which are essential for
enzymatic activity.
2
Metalloproteinase inhibitors. Secretion of
metalloproteinase in an inactive precursor form is
an important feature which regulates their activity
in extracellular milieu. Organomercurials activate
the proenzyme in vitro by inducing a conformational
change. This reaction removes the amino terminal
pro-segment, permanently converting the enzyme
to the active form. Other mechanisms of activation
may involve oxidants or serine proteinase. Further
regulation of the activity of metalloproteinases
in the extracellular milieu is achieved by specific
inhibitors interacting with the activated enzymes.
Metalloproteinases can be inhibited by
macroglobulin, a 725 kDa plasma proteinase
inhibitor whose inhibitory properties are not specific
and markedly different from all other known inhibi-
tors.:7 Two tissue inhibitors of metalloproteinases
(TIMP) have been characterized and cloned. TIMP-1
is a glycoprotein present in many tissues and
biological fluids. It is secreted by several mammalian
cell types, including fibroblasts, endothelial cells,
smooth muscle cells and chondrocytes.85 The
isolation and cloning of a second metalloproteinase
inhibitor, also called MI or TIMP-2, raises the
question of the existence of a family of TIMP-like
proteins. TIMP-2 displays 40% amino acid sequence
homology with TIMP-1, with conservation of all
twelve cysteine residues.8-e Both TIMP interact
only with the activated enzyme and it has been
shown that TIMP-2 has another regulation role
which involves blocking the autoproteolytic activa-
tion of procollagenase.89 The activity of TIMP is
inhibited by different serine proteinases, including
human neutrophil elastase, trypsin and
chymotrypsin.9 In addition, it seems that TIMP can
be oxidatively regulated.
Serine proteinases. Serine proteinases are a large
family of enzymes whose active site comprises the
so-called ’catalytic triad’ of histidine, aspartic acid
and serine, in which a charge relay system allows the
histidine and the aspartic acid to transiently bind a
proton from the serine which can then attack the
peptide bond in the target protein. In the azurophilic
granules of the neutrophil, the group of the neutral
serine proteinase homologues includes cathepsin G,
elastase, proteinase 3 and azurocidin. Because they
also possess microbicidal activity distinct from their
proteolytic capacity, they will be referred to as
serprocidins. Members of this family are cationic
glycoproteins of similar size (25-29 kDa). They
have all been cloned.94-9 The serprocidins exhibit
sequence homology between each other and with
T cell proteinases, human lymphocyte proteinase,
granzyme B, and rat mast cell proteinase.
13,95,9 Clon-
ing of the genomic segment that contains the func-
tional genes for neutrophil elastase, proteinase 3
(PR3), also called p29b or myeloblastin, and
azurocidin, also called CAP37, has revealed that
these genes form a cluster of genes, located in the
terminal region of the short arm of chromosome 19
and are coordinately down-regulated in the
promonocytic cell line U937 during induced terminal
differentiation.99 The gene of cathepsin G belongs to
another cluster of genes encoding haematopoietic
serine proteinases together with granzyme H and
granzyme B genes on chromosome 14q11.2.
Two well studied serprocidins include neutrophil
elastase and cathepsin G. The remaining two, PR3
and azurocidin, more recently isolated and cloned,
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were identified as a result of a general screening
for neutrophil-derived antibiotic proteins.12,13
Neutrophil elastase and PR3 display very similar
patterns of proteolytic activities.TM They are both
capable of cleaving insoluble elastin and a variety of
matrix proteins, including fibronectin, laminin,
vitronectin and collagen type IV. They show minimal
activity against interstitial collagens, type and
III.l5’16 As a result, neutrophil elastase and PR3 have
been shown to induce experimental pulmonary
emphysema.17-19
Although the azurocidin sequence reveals exten-
sive homology with serine proteinase, and in particu-
lar with neutrophil elastase, two amino acid substi-
tutions, His--+Ser and Ser--)Gly, in the catalytic triad
nullify its enzymatic activity.95
Cathepsin G shows little enzymatic activity com-
pared with elastase. Nonetheless, specific substrates
have been used to probe its proteolytic activity.
Thanks to their proteolytic activity, serprocidins have
been shown to be involved in platelet aggregation.
Purified cathepsin G activates platelets in terms of
aggregation, serotonin release, calcium movements
and thromboxane B,. formation. 11,111 Although
neutrophil elastase or PR3 alone is unable to trigger
platelet activation, each enhances cathepsin G in-
duced platelet activation when added in combina-
tion with cathepsin G.12
Serine proteinase inhibitors. Neutrophil elastase,
cathepsin G and PR3 are typical serine proteinases,
which are rapidly inactivated by di-isopropyl
fluorophosphate, synthetic acylating inhibitors3 and
specific serine proteinase inhibitors. The use of in-
hibitors seems to be the only way to regulate their
activity inasmuch as these proteinases are probably
functional in their packaged forms. Most likely the
dipeptide activation fragment acts to process the
enzyme for localization in the azurophilic granules;
indeed, the nature of the enzyme responsible for the
proteolytic cleavage is unknown.TM Several human
proteins function as potent inhibitors of elastase.
Each has a characteristic physiological location, likely
equivalent to its principal site of inhibitory action.
The host’s primary defence against uncontrolled
elastase-mediated damage is zl-proteinase inhibitor
(zl-PI, formerly termed (zl-antitrypsin). Synthesized
by hepatocytes, zl-PI is a 52 kDa glycoprotein,
present at highest concentrations in plasma, but also
found in human azurophilic granules.15 Its high
plasma concentration accounts for more than 90% of
the elastase inhibitory capacity of human plasma.16
zl-PI belongs to the serpin family composed of
structurally homologous serine proteinase inhibitors.
Interestingly, this typical tertiary structure is found in
ovalbumin, one of the several members of the family
with no known inhibitory function.17 Members of
this family have been identified in plants, insects and
throughout the animal kingdom.
18 Most serpins are
found in extracellular fluids but cytosolic serpins
have been found in a wide variety of mammalian
PMNs.19,120
When serpins interact with their cognate enzymes,
a covalently stabilized serpin-enzyme complex is
formed. The interaction results in a change in the
conformation of the inhibitor. It has been shown that
a pentapeptide domain in the carboxy-terminal frag-
ment of czl-antitrypsin, which is highly conserved
among the serpin family, is recognized by a specific
cell surface receptor, the serpin enzyme complex
(SEC), and through this SEC receptor is linked to
several important physiological processes well char-
acterized in the case of czl-PI, such as upregulation
of the synthesis of (zl-PI itself, internalization and
endosomal/lysosomal degradation of SEe. 121-123
Current concepts on the pathogenesis of emphy-
sema largely emphasize the role of unrestrained
proteolytic activity in the lung extracellular matrix.
Since (zl-PI provides almost all the protective screen
of the lower respiratory tract against neutrophil
elastase, emphysema might result from inactive
otl-PI unable to inhibit neutrophil elastase in the
lung. 124’25 Of particular interest is (zl-PI deficiency, an
autosomal hereditary disorder characterized by re-
duced levels of zl-PI in plasma and lung fluids,
thereby leading to unopposed proteinase activity
and culminating in pulmonary emphysema. The de-
ficiency of otl-PI results from various mutations
in five {xl-PI coding exons.26 Moreover, this absence
of a normal anti-neutrophil elastase screen permits
free elastase to bind to alveolar macrophages,27a2s
resulting in the release of leukotriene B (LTB4) a
process which attracts neutrophils to the alveoli of
zl-PI-deficient individuals, thus accelerating the
lung destruction that characterizes this disorder.29
Several strategies of czl-PI augmentation therapy for
(zl-PI deficiency can be used in order to restore a
normal level of 0tl-PI. An original approach con-
sists in using endothelial cells as target for gene
therapy of 0tl-PI deficiency, since the modified
endothelial cell would secrete human zl-PI directly
to the circulation, where it would diffuse into the
alveolar interstitium, providing protection against
neutrophil elastase. A modified adenovirus has been
shown to transfer 0tl-PI cDNA into human
endothelial cells, thus conferring upon the cells the
ability to synthesize and secrete (zl-PI capable of
combining with neutrophil elastase.TM
As for metalloproteinases, ot2-macroglobulin in-
hibits elastase activity.6 Another cell protein that
inhibits leukocyte elastase is the secretory
leukoproteinase inhibitor (SLPI), a 12 kDa non-
glycosylated protein which is produced by cells of
mucosal surfaces and found in the corresponding
epithelial fluids, including in the lung. The molar
concentrations of SLPI in total respiratory tract
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epithelial lining fluid (ELF) are 56 _+ 10% that of
PI, suggesting that SLPI may be important for local
anti-elastase protection. However, despite its rela-
tively high concentration, functional studies have
shown that only one-third is operative. Moreover, in
vitro studies showed that exposure to oxidants com-
bined to elastase causes the molecule to be cleaved
from a 12 to an 8 kDa inactive fragment. It is conceiv-
able that SLPI plays a first-line role, particularly in the
upper airway where its concentration is highest. SLPI
might be useful therapeutically in helping to aug-
ment the anti-elastase defences of the lung. 13" In an
experimental rat model of immune complex-induced
alveolitis, recombinant SLPI intra-tracheally instilled
provided significant protection against pulmonary
damage,m
A small acid-stable polypeptide of 7 kDa, elafin, is
found in skin and appears to be an elastase inhibitor.
Human monocyte/neutrophil elastase inhibitor, a
42 kDa glycoprotein, and member of the serpin
family, has recently been isolated and cloned.19,a34
A study of the reactive centre residues indicates that
this new serpin seems to inhibit more than one
proteinase and is likely to be oxidation sensitive. The
latter feature would limit the sphere of action of E1
to the immediate vicinity of carrier cells, thus regu-
lating the proteolytic action of the neutrophil itself.
The substrate specificities of PR3 being so close to
those of elastase, the pattern of inhibition with serine
proteinase inhibitors are almost the same. PR3 can be
inhibited by I-PI, 2-macroglobulin or elafin, but
not by SLPI. In addition, PR3 is able to selectively
degrade both native and oxidized SLPI.5 Its sensitiv-
ity to monocyte/neutrophil EI is unknown.
Cathepsin G displays a different pattern of inhibi-
tion, inasmuch as the serpin which accounted for the
greatest inhibition is l-antichymotrypsin (I-AC).
Moreover, elastase-l-PI and cathepsin
antichymotrypsin complexes are chemotactic for
neutrophils, this effect being mediated by the SEC
receptor.1-18 As for oxidant scavengers, synthetic
proteinase inhibitors of narrow specificity have been
developed to probe the involvement of proteinases
in biological processes.
Microbicidal and antibiotic activities of
serprocidins. Among purified neutrophil-derived
proteinases, those that so far appear to have signifi-
cant antibacterial potential independent of their
enzymatic action are cathepsin O139’4 and PR3.
6
The antimicrobial potential of the proteinases
could be expressed through an indirect mechanism
involving antibiotic peptides synthesized as
proforms, such as defensin.14a42
It is unknown how these antibiotic proteins stored
in the granules as inactive proproteins undergo
proteolytic cleavage for conversion to active
cytotoxins, or where and when in the course of
granulopoiesis this happens. However proteinases
could be good candidates able to process and acti-
vate these antibiotic proteins, thus revealing an im-
portant role for these enzymes in antimicrobial
events. 13
Role ofproteinases in healing and wound repair.
Phagocytes, predominantly neutrophils and
macrophages, play a critical role in early control of
wound repair,m The movement of these cells is
directed by the numerous chemoattractant sub-
stances that result from degradation of bacteria and
autologous proteins. 144,145 The predominant action of
the neutrophil in the wound is to express
degradative enzymes and to provide an antibiotic
shield through production of ROI and the release of
antibiotic peptides. In the skin, neutrophils are re-
sponsible for the release of a variant form of
collagenase, gelatinase and elastase. Proteinases par-
ticipate both in destruction of invading micro-organ-
isms and in removal of cellular and matrix debris. In
addition, at least at some inflammatory sites,
neutrophils can release other soluble signals such as
IL-8, IL-1 and TGF-beta.46
Serprocidins as target antigensfor antineutrophil
cytoplasmic antibodies. Serprocidins are now recog-
nized to be target antigens for antineutrophil cyto-
plasmic antibodies (ANCA) found in sera of patients
with vasculitis, glomerulonephritis or other systemic
inflammatory syndromes. When observed by indirect
immunofluorescence microscopy on alcohol fixed
PMN, ANCA can be divided into a group displaying
a cytoplasmic staining pattern (C-ANCA) and a
second group displaying perinuclear staining
(P-ANCA).47 Investigations of antigen specificity
have been aimed at identifying the proteins recog-
nized by these AREA.48 It appears that the majority
of C-ANCA react with PR3, although in a few cases
C-ANCA could be directed against BPI, elastase149 or
cathepsin G.15 The major target antigen of P-ANCA
is myeloperoxidase.TM
Despite difficulties in classifying vasculitic syn-
dromes, the correlation between clinical expression
of Wegener’s granulomatosis and ANCA reactivity
has now well established that PR3 is the target
autoantigen.52,53 The pathogenesis of this form of
immune necrotizing vasculitis that involves neither
antibody directed against basement membrane nor
immune complex deposition is only beginning to be
understood.TM Whether ANCA are serologic epiphe-
nomena or play a pathogenic role in the course of the
disease is still a matter of debate.
Many studies have focused on in vitro
ANCA-induced activation of neutrophils and conse-
quent damage to endothelial cells. It is possible that
ANCA target antigens such as PR3 translocate to the
cell surface to bind ANCA and then trigger the res-
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piratory burst and subsequent release of ROI. 155,156
Other studies have been directed at characterization
of these autoantigens, thus pointing out that there
are different species of C-ANCA that bind different
epitopes of PR3 thus increasing the difficulty of
assessing the pathophysiological meaning of these
ANCAs.157,158
ROI and proteinases in the modulation of
inflammation
Cooperation between ROI and proteinases in host
tissue damage: Modulation of the proteolytic capac-
ity of neutrophils by their chlorinated oxidants relies
on their ability to inactivate serine proteinase inhibi-
tors by oxidation as well as to activate latent
metalloproteinases such as collagenase or gelatinase,
thus potentiating the resulting deleterious effect of
the proteinases. 159
The zl-PI contains a methionine residue critical to
its activity at position 35816 which can be oxidized
and thus inactivated by hypochlorous acid or
chloramines from activated neutrophils. Oxidation of
Met-358 causes a 2 000-fold decrease in the rate of
association between neutrophil elastase and the
modified antiproteinase. Recombinant zl-PI resistant
to oxidation does not undergo inactivation and effi-
ciently protects connective tissue from neutrophil
damage. 161a62 Some nonsteroidal anti-inflammatory
drugs appear to rescue czl-PI from oxidative inactiva-
tion by efficiently limiting the extracellular availabil-
ity of HOC1 in the neutrophil surroundings. 163 Inas-
much as both z2-macroglobulin and SLPI appear to
be sensitive to oxidation, the complete anti-elastase
defence is regulated by neutrophil-derived chlorin-
ated oxidants. The direct effect of oxidant attack on
elastase using free radicals produced in a Fenton
reaction (H,.O,. in the presence of copper) shows that
elastase, as well as three of its inhibitors, eglin c, zl-
PI and SLPI, are efficiently inactivated. 164 Study of the
effect of chloramines on z-chymotrypsin, another
serine proteinase, has shown that oxidation barely
modifies its catalytic properties, whereas sensitivity
to specific proteinase inhibitors is decreased. 165 Study
of the synergy between myeloperoxidase-HiOa-
chloride system and elastase in degrading endothel-
ial cell matrix heparan sulfate proteoglycan has
shown that elastase alone, and the myeloperoxidase
system alone, cause degradation, and when a 4 h ex-
posure to elastase was followed by 15 min of the
myeloperoxidase system, the effect was greater than
additive. No such effect was seen when both systems
were added together, or when elastase followed the
myeloperoxidase system. 166 Studies of the interac-
tions of elastase with its insoluble substrate, elastin,
have shown that elastase forms a stable complex
with elastin-derived peptides during elastinolysis
and, as a result, elastin derived peptides could con-
tribute to modulation of the proteolytic activity of
elastase.6:
Metalloproteinases are stored in latent form within
granules. When neutrophils are stimulated to release
their lysosomal enzymes, these latent enzymes must
be activated before they can attack their substrate.
The mechanisms by which neutrophil-derived oxi-
dants activate latent metalloproteinases is still not
completely understood, but latent collagenase can
be activated by HOC1 whereas progelatinase seems
to require both oxidant- and serine proteinase-
dependent pathways.6<7 Some reports indicate
that cathepsin G is a key mediator in neutrophil
collagenase activation, and that HOC1 under certain
conditions leads to activation of collagenase or the
stimulation of cathepsin G ability to activate
neutrophil collagenase. 171 Moreover, the activity of
metalloproteinases is also regulated via their specific
inhibitors, the TIMPs, which can be inactivated by
oxidation or proteolytic cleavage.9,172 The modula-
tory effect of ROI on neutrophil-derived serine
proteinases and matrix metalloproteinases appears to
be of crucial importance in the inflammatory lung
process where these enzymes play a key role in acute
lung damage. The co-administration of the serine
proteinase inhibitor SLPI and the metalloproteinase
inhibitor TIMP significantly prevents pulmonary
damage in a rat model of immune complex-induced
alveolitis,m The inactivation of human otl-PI can
occur by interaction with bacterial proteinases such
as seryl-cysteinyl- and metalloproteinases from
Staphylococcus aureus. This process of inactivation
of zl-PI by pathogenic proteinases could amplify
dysregulation of elastase activity during septi-
caemia. 173
Of special relevance in the study of proteinases/
antiproteinases and oxidant/antioxidant balances is
the case of cystic fibrosis. Cystic fibrosis is a heredi-
tary disorder caused by mutations of the cystic fibro-
sis transmembrane conductance regulator (CFTR) the
product of which is a membrane protein thought to
function as a chloride channel. The lethal clinical
manifestations are clearly related to the thick, in-
fected mucus and chronic neutrophil-dominated air-
way inflammation. 174-76 In these patients, chronic
airway infection, especially by Pseudomonas
aeruginosa, is of critical important in prognosis. This
pathogen can never be permanently eradicated de-
spite intensive antibiotic treatment and leads invari-
ably to respiratory failure, which is the cause of death
in most patients with cystic fibrosis. It is now well
established that neutrophil-derived oxidants inacti-
vate antiproteinases such as otl-PI, thus potentiating
the deleterious effects of elastase. Moreover, anti-
proteinase imbalance has been recognized as a factor
favouring the persistence of Pseudomonas aeru-
ginosa. 177-179 In order to increase local antipro-
teinase defence, different aerosol treatments have
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been tested in cystic fibrosis patients. Aerosol admin-
istration of 0tl-PI efficiently suppresses the burden
of active elastase on the respiratory epithelial sur-
face.Is Likewise aerosolized recombinant SLPI re-
duces elastase levels and lung inflammatory state.
181
Interactions ofROIandproteinases with pro-inflam-
matory cytokines: There is now evidence for several
possible functional points of contact between ROI
and proteinases, on the one hand, and cytokines, on
the other. Cytokines can be regulated at different
levels, e.g. the molecule itself, its inhibitor or its
receptor, and at different stages such as transcription,
synthesis or activity. An additional level of regulation
is possible inasmuch as the effector mechanisms of
cytokine activities could involve ROI interacting with
transcription factors.
Given the wide diversity of cytokines involved in
the control of the inflammatory process and the
immune response,
182 we will focus only on tumour
necrosis factor-{z (TNF{z) and the chemokine IL-8,
both of which are able to activate neutrophils and
trigger ROI generation. They will be used as repre-
sentative examples in our discussion.
Tumour necrosis factor. TNFz is a cytokine
which has important functions in coordinating im-
munological and inflammatory responses. TNFcz is
released primarily by activated macrophages and
induces changes in cell shape, differentiation and
proliferation of a variety of cell types, including T and
B cells, neutrophils, macrophages, thymocytes,
endothelial cells, keratinocytes, glial cells and
fibroblasts.83 The interaction betweenTNF and ROI
is two-way since TNFot induces neutrophils to pro-
duce ROI,84-186 which in turn acts on TNFot expres-
sion and release. Lastly, ROI seem to be involved in
the transduction pathway of TNFcz as well as in its
transcription control through the nuclear factor NF
kappa 8.187
Evidence suggests that ROI might provide a posi-
tive signal for the release of TNFz and, in various
cells, TNFz-mediated cell lysis can be inhibited by
thioredoxinle or N-acetylcysteine, a thiol antioxidant
and GSH precursor.
89q91 TNFo: induces oxidative
stress in isolated mouse hepatocytes. Hepatocytes
exposed to a TNFcz concentration that does not
induce cell toxicity exhibited intracellular GSH de-
pletion and GSSG efflux during the first 2 h of
exposure, followed by a decrease in cellular ATP
content. The antioxidants mannitol and benzoate, as
well as the iron chelator desferoxamine, reduce the
extent of TNFot induced oxidative stress, suggesting
involvement of the hydroxyl radical. 192 In mesangial
cells, TNFz, as well as aggregated IgG, increase
mRNA levels for the monocyte chemoattractant pro-
tein, JE/MCP-1, and the colony-stimulating factor,
CSF-1. Superoxide anion generated by the xanthine
oxidase system, but not H202 increases mRNA levels
for both JE/MCP-1 and CSF-1. Addition of NADPH to
activate membrane bound NADPH-oxidase depend-
ent superoxide generating system increases mRNA
levels and further enhances stimulation by TNFot. It
appears that generation of ROI, possibly via a
NADPH-oxidase pathway, is involved in the induc-
tion of JE/MCP-1 and CSF-1 genes by TNFz and
aggregated IgG complexes.93 The finding that
pretreatment of sensitive targets with TNFot induces
resistance to TNFot was attributed to the synthesis of
the mitochondrial form of superoxide dismutase,
MnSOD.TM Moreover, cellular sensitivity and resist-
ance to TNFz are correlated, respectively, with de-
creased and increased levels of superoxide
dismutase. The effect of TNFcz on the expression of
antioxidant enzymes has been studied in TNFz
sensitive myeloid cell lines and in normal peripheral
blood lymphocytes and monocytes. Exposure to
TNFot induces a striking increase in manganese
superoxide dismutase (MnSOD) RNA levels whereas
no changes are observed in the case of copper-zinc
superoxide dismutase (Cu/ZnSOD) or glutathione
peroxidase. Furthermore, TNFz resistant leukaemic
cell lines have higher constitutive levels of MnSOD
RNA and activity, and these levels do not change in
the presence of TNFo:.95 The effects of IL-1, TNFot
and LPS treatment on the expression of superoxide
dismutases have been studied in both rat pulmonary
artery and microvascular endothelial cells. Similar
results were obtained insofar as these mediators
produced an increase in MnSOD but not Cu/ZnSOD
expression in both tested cell lines. 196 In contrast,
another study showed that two cell lines in which
mutants have been selected to be resistant to
cytolysis by TNFz behave differently. The SK-MEL-
109 variants had relatively low levels of MnSOD that
were inducible by TNFcz; the HeLa variants had very
low levels of MnSOD that were poorly inducible by
TNFx. It was thus concluded that an elevated level
of MnSOD was not required to protect these cells
from TNFz mediated cytolysis.97
Glutathione appears to be of critical importance in
TNFcz-mediated effects. In bovine pulmonary
microvascular endothelial cells, stimulation with
TNFt increases the permeability induced by H202, at
a concentration which by itself has no effect on the
permeability of endothelial cells. Pretreatment with
TNF0t for 6 h had no direct effect on transendothelial
permeability. However, this TNF0t pretreatment en-
hanced the susceptibility of endothelial cells to H202.
Measurement of intracellular antioxidant content fol-
lowing exposure to TNFcz revealed a decrease in
reduced GSH and an increase in the oxidized form
(GSSG), whereas no change in catalase content could
be detected. The decrease in oxidant buffering ca-
pacity secondary to TNF{z-induced reduction in
intracellular GSH content mediates the increased
susceptibility of endothelial cells to H202.198 The
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same type of study has been performed with phorbol
myristate acetate (PMA)-activated neutrophils as ROI
generating system. Challenge of neutrophils layered
on TNFtx-pretreated endothelial cells with PMA in-
creases permeability. In contrast, challenge of CGD-
neutrophils fails to induce any change in endothelial
cell permeability. 199
It is still unclear whether ROI are implicated in
TNFtx-induced injury derived from the phagocyte
respiratory burst or from the action of xanthine
oxidase, and further studies are needed to address
this issue. However, it is possible that intracellular
ROI may result in the activation of genes responsible
for apoptosis, conceivably through an oxidative
stress-responsive nuclear transcription factor such as
NF-kappa B.
The regulatory effect of H,.O,. on both the cytotoxic
activity and the specific binding of TNFot was studied
in TNFot-sensitized murine L929 cells. Half-hour
pretreatment with H202 altered cell sensitivity to
TNFct, whereas H,.O,. preatreatment did not modify
TNFct activity. The inhibitory effect of H,.O,. was
suppressed by catalase; but was unaffected by the
scavengers of OH- and HOC1, suggesting that
and not one of its metabolites, was responsible for
this inhibition. The H,.O,. effect was associated with
an approximately 50% decrease in density of cell
membrane TNFtx receptors, without any change in
their affinity. Moreover H,.O,. did not affect the rate of
degradation of TNF0t receptors. It appears that H202
can down-regulate the cellular response to TNFtx,
possibly by reducing its binding capacity,am
A growing body of evidence has emerged support-
ing the implication of proteinases in the modulation
of cellular responses to cytokines,
2" and especially to
TNFcz. Specific proteolytic cleavage of the molecules
themselves can lead to release of membrane an-
chored precursors, facilitate secretion and abolish or
generate biological activities. As a result, proteolysis
can affect specific cell surface receptors and free their
extracellular domains to circulate as soluble inhibi-
tors of cytokine activity.
Two types of TNFtx receptors have been isolated
in the human and their genes have been cloned and
structure activity studies carried out.23-26 The type
receptor is a 55 kDa molecule which is expressed
preferentially in cells of epithelial origin, whereas the
75 kDa type II receptor is more abundant in myeloid
cells, human neutrophils and monocytes, expressing
similar amounts of each receptor at their surface. The
mechanisms of TNFtz receptor shedding are still not
completely understood. The release of either type
or type II receptor seems to involve different
proteolytic pathways. A first TNFtx releasing activity
has been localized in azurophilic granules and iden-
tified by its inhibitory pattern as elastase. This en-
zyme preferentially acts on the p75 TNFtz receptor of
neutrophils and mononuclear cells, releasing a solu-
ble fragment of 32 kDa that retains its ability to bind
TNFct. A second TNF0t releasing activity insensitive to
serine-proteinase inhibitor is operative in intact
fMLP-stimulated neutrophils, shedding a 42 kDa frag-
ment from the p75 TNF0t receptor and a 28 kDa
fragment from the p55 TNF0t receptor.
27 It appears
that the mechanisms underlying TNFtx receptor
shedding involve proteinases other than serine
proteinases contained in azurophilic granules, and
further studies are needed to localize and identify
these proteinases.
The pathophysiological importance of the interac-
tions between oxidants, proteinases and pro-inflam-
matory cytokines has been extensively studied by
our own group in patients with end-stage renal
disease receiving haemodialysis therapy.
28 It is now
clear that each dialysis session triggers neutrophil
activation, mainly through the generation of acti-
vated complement components following the con-
tact of blood with bioincompatible dialysis mem-
branes.’9 This is evidenced by massive generation of
ROI’ and the presence of high levels of neutrophil
elastase and tx1-PI.21 This perdialytic activation con-
trasts with an overall depression in the expected
responses of these cells to pathogens, e.g.
chemotactic, phagocytic and oxidative response ca-
pacities.
’p Among the numerous side effects of ROI
that could account for dialysis related complications,
the possibility that they could contribute to [32
microglobulin amyloidosis arthropathy, by inducing
fragmentation, polymerization and thus favouring
subsequent intra-articular deposit of ]32 micro-
globulin, has recently been raised by our study of the
effect of defined radiolytically generated oxygen
species on [32 microglobulin structure.41
Acting in concert with neutrophil-derived ROI and
proteinases, monocyte-derived circulating pro-
inflammatory cytokines could also play a critical role
in dialysis related chronic inflammatory process and
contribute to the underlying immune system
dysregulation associated with uraemia.’3
Recently, high levels of both TNF-sR55 and
TNF-sR75 and an imbalance between TNFa and its
soluble receptors, acting as naturally occurring in-
hibitors,
’14 have been reported in dialysis pa-
tients. ’15,’16 It thus seems that as with the oxidant/anti-
oxidant balance the cytokine/anti-cytokine balance
could play a critical role in complications observed in
long-term dialysis patients.
Interleukin-8. IL-8 belongs to a novel class of small
cytokines, now called chemokines, which are widely
studied because of their ability to activate leukocytes
and their potential role as mediators of inflammation.
IL-8 has been described as a potent neutrophil
chemoattractant and activator. 217 Studies using whole
blood as a model of cytokine production have
shown that the OH- scavenging agent dimethyl
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sulfoxide (DMSO) drastically inhibits IL-8 production
in blood stimulated with lipopolysaccharide (LPS)
or other agents such as TNF0t, IL-I,
phytohaemagglutinin A (PHA) and aggregated im-
mune complexes.
’18 However, using the same whole
blood model, in both normal individuals and CGD
patients, DMSO inhibitable production of IL-8 could
be triggered in response to LPS, PHA or aggregated
immune complexes. Direct exposure to H20 stimu-
lates IL-8 production in a concentration-dependent
manner in a hepatoma cell line, Hep-G2, a pulmo-
nary type II epithelial cell line, A549, and human skin
fibroblasts.
,.19 It seems that ROI are important regula-
tors of IL-8 expression whether or not they are
derived from NADPH oxidase activation.
Oxidative regulation of IL-8 activity could be me-
diated through its receptor. Studies in neutrophils
have shown that two sulfhydryl groups participate in
the binding of the ligand to the receptor and conse-
quently regulate receptor-mediated cell functions. ,.,.
There is evidence that neutrophil-derived
proteinases are involved in the control of IL-8 pro-
duction. The fluid lining the respiratory epithelium in
cystic fibrosis contains large numbers of neutrophils
and, consequently, active neutrophil elastase.
Neutrophil elastase appears to be the mediator re-
sponsible for inducing bronchial epithelial cells to
express IL-8 gene and release neutrophil chemotactic
activity. In addition, neutrophil elastase inhibitors
prevent IL-8 gene expression.
,.21,2= Aerosolization of
recombinant SLPI in patients with cystic fibrosis sup-
presses the neutrophil elastase burden on the respi-
ratory epithelial surface and at the same time greatly
reduces IL-8 levels, thus decreasing the number of
PMN in the epithelial lining fluid.TM The role of IL-8
in lung inflammatory reactions has been demon-
strated by the protection afforded by treatment with
an anti-IL-8 monoclonal antibody in a model of E-
selectin-dependent lung injury.
’,.3
Studies of the modulation of IL-8 production have
revealed the critical role of ROI or proteinases alone
or in combination. These new findings could form
the basis of new therapeutic practice in the manage-
ment of inflammation.
Interactions of ROI and proteinases with adhesion
molecules: The interaction of neutrophils with
endothelial cells, one of the first events in the acute
inflammatory response, induces profound changes
in the biosynthesis of potent endothelial modulators.
Although it has been known for more than a decade
that endothelial cells can be damaged in vitro by
neutrophil derived ROI, 224’225 it is now apparent that
sub-injurious concentrations of ROI could alter the
physiologic status of endothelial cells and modify
their response to inflammatory mediators.
Mechanisms of endothelial cell killing by
neutrophil-derived ROI can be blocked by
superoxide dismutase, catalase, iron chelators or
scavengers of the hydroxyl radical. There is evidence
that products from xanthine oxidase of endothelial
cells are necessary for the toxic effects of hydrogen
peroxide or phorbol ester-activated neutrophils.
Conversion of xanthine dehydrogenase to xanthine
oxidase in endothelial cells occurs during contact of
endothelial cells with neutrophils. This conversion
is not related to neutrophil-derived ROI.=6 The
glutathione redox cycle has been shown to protect
cultured endothelial cells against lysis by
extracellularly generated H202227 and appears to be
critical for the survival of tumour cells exposed to
H202o228
Adhesion of circulating PMN to endothelial cells is
a critical step in the inflammatory process. This com-
plex cell/cell interaction requires increased expres-
sion of surface adhesive molecules either on
neutrophils or on endothelial cells. The adherence of
human neutrophils to human endothelial cells in
vitro is increased by chemotactic stimulation of the
neutrophils,
=9,,.3 or by stimulation of endothelial
cells with endotoxin
,.3 or cytokines such as TNF or
IL-I.
,.’-,.5 It has been recognized that within the
post-capillary venules of inflamed tissue, emigrating
leukocytes leave the central stream of the circulation,
roll more slowly along the vessel wall, then stop by
adhering tightly to the endothelial surface before
squeezing between adjacent endothelial cells into
the sub-endothelial tissue. ,.6 More recently, it has
been appreciated that the rolling phenomenon is
mediated by the selectin class of adhesion molecules,
while the leukocyte 2 integrins (CDll/CD18) and
their endothelial counterreceptors, (intercellular
adhesion molecule or ICAM) are involved in the tight
adhesion.
,.37-,.9 CD11/CD18 receptors on neutrophils
are known to modulate chemotaxis, neutrophil/
neutrophil aggregation, neutrophil adhesion and
transvascular migration.
,.4 In addition, other adhe-
sion molecules are involved in transendothelial mi-
gration of leukocytes such as the platelet/endothelial
cell adhesion molecule 1 (PECAM-1).24’242 Recent
evidence indicates that ROI and proteinases modu-
late adhesion molecule functions. In a model of cat
mesenteric venule, H,.O,. and chloramines but not
HOCl, promote leukocyte adhesion to venular endo-
thelium. HaO,.-induced CD18-mediated leukocyte
adherence appears to be elicited by PAF and
by a direct effect of the oxidant on CD11/CD18
expression.
Treatment with low concentrations of H20 (50 to
100 l.tM) selectively increases the surface expression
and mRNA levels of ICAM-1 and major
histocompatibility complex class I, but not
endothelial E-selectin, vascular cell adhesion mol-
ecule-1 (VCAM-1), or gp96, a constitutively ex-
pressed endothelial cell surface protein. H,.O,. does
not activate the transcription nuclear factor kappa B,
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an important mediator of TNFx-induced gene ex-
pression. It seems that subinjurious doses of H202
can activate endothelium, the molecular mechanisms
underlying this phenomenon differing from those of
inflammatory cytokines. 243 After exposure to the
hypoxanthine/xanthine oxidase ROI producing sys-
tem, human umbilical vein endothelial cells display
increased adherence to resting neutrophils, com-
pared with untreated endothelial cells. ICAM-1, con-
stitutively present on the surface of resting
endothelial cells, is involved in neutrophil adherence
to ROI treated cells, since this adherence is inhibited
by anti-ICAM1, anti-CDlla, anti-CDllb and anti-
CD18 monoclonal antibodies. ’44 Another study
showed that endothelial cells exposed to H202 ex-
press the granule membrane protein-40 (GMP-40),
which can be translocated from its intracellular stor-
age pool to the surface of endothelial cells where it
acts as a ligand for neutrophil adhesion. 245 Similar
results were obtained in an in vitro model of
hypoxia/reoxygenation induced endothelial free-
radical generation and adhesion of resting PMN.
Oxidative stress induced an increase in the expres-
sion of GMP-40 as well as de novo synthesis of
endothelial adhesion molecule 1 (ELAM-1) on the
endothelial surface, these effects being blocked by
free radical scavengers. 246
One possible interaction between proteinases and
membrane proteins such as adhesion molecules, is
proteolytic cleavage, leading to soluble factors, as
has been described for TNF receptors. It is well
documented that the circulating neutrophils respond
to inflammatory products by expressing surface
receptors appropriate to the inflammatory signal. ’47
Typically, this expression involves exposure or func-
tional activation of opsonin receptors including
receptors for Fc fragment of IgG (FcyR) and receptors
for complement components. Neutrophils possess
two classes of FcyR which have different functions,
as well as different sensitivity to proteolytic cleavage
by neutrophil elastase. FcyRII (CD32) is made up of
an external opsonin-binding portion, a membrane
domain and a cytoplasmic tail, whereas FcyRIII
(CD16) is anchored to the phagocyte membrane
through a phosphatidylinositol linkage. FcyRII,
which is resistant to elastase, is primarily responsible
for IgG mediated activation of human PMN
since FcyRIII, which is sensitive to elastase, binds
immune complexes without directly activating
neutrophils. 248
Complement receptors include the opsonin
receptor CR1 (CD35) which binds C3b and C4b, the
chemotactic receptor for C5a and CR3, a member of
the integrin family (CD11b/CD18 or Mac-l) which
recognizes C3bi and ICAM as its endothelial counter-
part receptor. Expression of both CR1 and CR3 is
increased upon neutrophil activation249 and in the
presence of cytokines.2s
Interestingly enough an upregulation of CR3 on
both monocytes and neutrophils has been reported
in dialysis patients during the session251 providing a
molecular mechanism for dialysis induced neutrophil
sequestration in the pulmonary vascular bed.
The expression of both CR1 and CR3 has also been
studied in circulating or bronchoalveolar lavage
(BAL) neutrophils in the case of cystic fibrosis pa-
tients compared with controls. In circulating
neutrophils, CR1 and CR3 expression was similar
both in cystic fibrosis patients and controls. In BAL,
CR3 expression was also similar to the controls,
whereas CR1 expression was significantly decreased
and neutrophil elastase was, at least in part, respon-
sible for the proteolytic cleavage of CR1. 252
Leukosialin is the major sialoprotein of human
leukocytes. 253’254 Due to the net negative charge of
leukosialin, its function may be to prevent nonspe-
cifi cell/cell interactions through negative charge
repulsions. Phorbol myristate acetate (PMA) or fMLP
activation of neutrophils reduces the expression of
leukosialin via a shedding mechanism, blocked by
both metalloproteinase and serine proteinase inhibi-
tors.255-57 Nonetheless, both exogenous and endog-
enous elastase have been reported to be responsible
for this shedding. Moreover, in participating in the
shedding of such a strongly anionic membrane pro-
tein which drastically modifies the neutrophil surface
charge, neutrophil-derived proteinases participate in
the regulation of the cell adhesion process.
In order to assess the in vivo role of elastase in
neutrophil adhesion and emigration, intravital
microscopy has been used to study PMN/endothelial
cell interactions in single inflamed post-capillary
venules in a model of platelet activating factor (PAF)
superfusion onto the mesentery. In vivo, elastase
significantly contributes to neutrophil infiltration, ag-
gregation, adhesion and emigration, these effects
being blocked by elastase inhibitors. Moreover, the
direct action of elastase on neutrophils assessed in
vitro indicates that neutrophil elastase directly
upregulates the subunit of the CD11/CD18
glycoprotein complex without any change in
t-selectin levels. Moreover, the increase in CD18
expression appears to be independent of
degranulation, superoxide anion production and cell
lysis. By selectively enhancing and regulating CD18
dependent chemotaxis, a rate-limiting step for other
neutrophil functions in vivo,5 elastase may modu-
late neutrophil infiltration and consequently the
overall migration process. ’59
Conclusions
A combination of reductionist and integrationist
approaches is rapidly expanding and revising our
understanding of the role of phagocyte-derived ROI
and proteinases. For nearly two decades, investiga-
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tion of the toxic potential of ROI prompted numer-
ous studies of different cell types aimed at describing
and characterizing the mechanisms of cell lysis, the
target cell involved and the defences used to coun-
teract ROI. Because of the new concept that ROI
could have a role as signalling molecules, investiga-
tion has focused on the effect of sub-lethal and non-
injurious concentrations of ROI on known biological
functions of given cell types. Studies of the involve-
ment of ROI and proteinases in different regulatory
processes suggest an overall system of cooperation.
A growing body of evidence supports this notion of
cooperation in the field of cytokines, as illustrated by
TNF0t and IL-8, and in the field of adhesion mol-
ecules, both fields having several points in common
with ROI and proteinases.
The neutrophil itself appears to be well equipped
with this unusual combination of contrasting mol-
ecules: ROI, small, ubiquitous and short-lived
molecules; and proteinases, macromolecules with
specific long-lasting activity. The neutrophil safely
keeps them apart through separate intracellular
compartmentalization under basal conditions. Never-
theless, in the defence of the host against pathogens,
their cooperation maximizes neutrophil microbicidal
potential as well as damage to host tissue. However,
the cooperation appears to be involved at another
level, where they act more as immunomodulatory
mediators than toxic weapons, in the whole inflam-
matory process. The overall picture is of a classical
alliance, for better and for worse.
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